Pseudocirrhosis Secondary to Metastatic Breast Cancer Diagnosed by EUS-Guided Liver Biopsy

Eidenschink, Benjamin; Peng, Hong; Paul, Navin

doi:10.14309/00000434-201810001-01303

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“… n.a. Yes Eidenschink et al 41 US 1 Breast 83 F Breast cancer cells n.a. 7.9 2.6 No Finocchi et al 42 Italy 1 Breast 46 F Breast cancer cells; fibrosis n.a.…”

Section: Resultsmentioning

confidence: 99%

Pseudocirrhosis and portal hypertension in patients with metastatic cancers: a systematic review and meta-analysis

Villani

Cosimo

Sangineto

et al. 2022

Sci Rep

View full text Add to dashboard Cite

Pseudocirrhosis is a clinical and radiological entity mimicking liver cirrhosis in patients without a history of chronic liver disease. We performed a systematic review and meta-analysis of the current literature to evaluate the state-of-the-art and investigate the epidemiology and clinical features of pseudocirrhosis. We searched PubMed, Web of Science and Scopus for literature published until February 28, 2022. We included in the final analysis 62 articles (N = 389 patients): 51 case reports (N = 64 patients), 5 case series (N = 35 patients) and 6 observational studies (N = 290 patients). About 80% of patients included in the case reports and case series had breast cancer. Most patients had at least one clinical sign of portal hypertension and ascites was the most common clinical manifestation of portal hypertension. The median time from pseudocirrhosis to death was 2 months (IQR 1–7 months). Alkylating agents and antimitotics were the most common classes of anticancer drugs reported in our study population. Notably, about 70% of patients received three or more anticancer drugs. Finally, pseudocirrhosis is a condition that occurs in patients with hepatic metastases and may have a negative impact on survival and clinical management of patients because of the potential development of portal hypertension and its complications.

show abstract

“… n.a. Yes Eidenschink et al 41 US 1 Breast 83 F Breast cancer cells n.a. 7.9 2.6 No Finocchi et al 42 Italy 1 Breast 46 F Breast cancer cells; fibrosis n.a.…”

Section: Resultsmentioning

confidence: 99%